Clinical Trial Update: Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This is a Phase 1/2 clinical trial evaluating GVV858 as a single agent or in combination with endocrine therapy for hormone receptor-positive, HER2-negative bre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Hormone Receptor-positive Breast Cancer
• Solid Tumors

Drugs mentioned

• GVV858

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase 1, Phase 2 | Status: RECRUITING